Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a common painkiller prevent a heart problem in preemies?

NCT ID NCT07067177

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving paracetamol (a common painkiller) early can prevent a heart opening called PDA from staying open in extremely premature infants (born before 30 weeks or under 1250 grams). 40 babies were randomly given either paracetamol or the standard drug indomethacin. The goal was to see which drug works better at closing the opening, with follow-up including heart scans and blood tests.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

40 people

The number who actually took part.

Started

Jan 2025

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 6 hours

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * gestational ages of \<30 weeks or birth weight below 1250 gm * inborn babies * authorization to perform the study signed by one of the parents after receiving enough information about the condition Exclusion Criteria: * Outborn babies * The presence of a significant birth defect or a congenital anomaly * Clinical instability that can lead to rapid death

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Patent ductus arteriosus (PDA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Al Ahli Hospital

    Hebron, Palestinian Territories

  • Makassed

    East Jerusalem, Palestinian Territories

  • Palestine Medical Complex

    Ramallah, Palestinian Territories

More trials for these conditions

Other studies related to the condition(s) this trial covers.